Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1970 1
1971 1
1978 1
1979 2
1980 1
1981 5
1983 2
1984 5
1985 1
1986 2
1987 1
1989 2
1991 1
1992 1
1993 1
1994 2
1995 1
1997 1
1998 1
1999 2
2000 3
2001 4
2002 2
2003 3
2004 7
2005 6
2006 1
2007 1
2008 1
2009 1
2011 1
2013 1
2014 1
2015 2
2016 5
2018 1
2019 1
2020 1
2021 2
2022 7
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study.
Sugimoto R, Satoh T, Ueda A, Senju T, Tanaka Y, Yamashita S, Koyanagi T, Kurashige T, Higuchi N, Nakamura T, Tanaka M, Azuma Y, Ohno A, Ooho A, Ooe M, Mutsuki T, Uchimura K, Kuniyoshi M, Tada S, Aratake Y, Yoshimoto T, Yamashita N, Harada S, Nakamuta M, Motomura K, Kohjima M; Liver disease Investigators’ Network of Kyushu University & Surrounding Hospitals (LINKS). Sugimoto R, et al. Among authors: kuniyoshi m. Medicine (Baltimore). 2022 Oct 7;101(40):e30871. doi: 10.1097/MD.0000000000030871. Medicine (Baltimore). 2022. PMID: 36221372 Free PMC article.
Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: kuniyoshi m. Aliment Pharmacol Ther. 2022 Aug;56(4):713-722. doi: 10.1111/apt.17107. Epub 2022 Jun 23. Aliment Pharmacol Ther. 2022. PMID: 35735794 Free PMC article.
Ectopic intrapulmonary thyroid.
Bando T, Genka K, Ishikawa K, Kuniyoshi M, Kuda T. Bando T, et al. Among authors: kuniyoshi m. Chest. 1993 Apr;103(4):1278-9. doi: 10.1378/chest.103.4.1278. Chest. 1993. PMID: 8131485
Biotransformation of bromosesquiterpenes by marine fungi.
Koshimura M, Utsukihara T, Kawamoto M, Saito M, Horiuchi CA, Kuniyoshi M. Koshimura M, et al. Among authors: kuniyoshi m. Phytochemistry. 2009 Dec;70(17-18):2023-6. doi: 10.1016/j.phytochem.2009.08.021. Epub 2009 Sep 21. Phytochemistry. 2009. PMID: 19772936
Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.
Sugimoto R, Motomura K, Ooho A, Aratake Y, Ueda A, Senju T, Tanaka Y, Yada M, Tanaka K, Kuwano A, Morita Y, Nagasawa S, Ooe M, Mutsuki T, Yoshimoto T, Yamashita N, Nakashima M, Hioki T, Koyanagi T, Higuchi N, Nakamura T, Harada S, Tanaka M, Tada S, Satoh T, Uchimura K, Kuniyoshi M, Nakamuta M, Kohjima M; Liver Disease Investigators' Network of Kyushu University & Surrounding Hospitals (LINKS). Sugimoto R, et al. Among authors: kuniyoshi m. Intern Med. 2022;61(21):3157-3164. doi: 10.2169/internalmedicine.9237-21. Epub 2022 Nov 1. Intern Med. 2022. PMID: 36328582 Free PMC article.
Terpenoids from Laurencia luzonensis.
Kuniyoshi M, Wahome PG, Miono T, Hashimoto T, Yokoyama M, Shrestha KL, Higa T. Kuniyoshi M, et al. J Nat Prod. 2005 Sep;68(9):1314-7. doi: 10.1021/np058004a. J Nat Prod. 2005. PMID: 16180805
Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: kuniyoshi m. J Infect Dis. 2022 Aug 26;226(3):431-440. doi: 10.1093/infdis/jiaa359. J Infect Dis. 2022. PMID: 32584386 Free PMC article.
Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for hepatitis C virus infection.
Ogawa E, Kawano A, Ooho A, Furusyo N, Satoh T, Takahashi K, Kajiwara E, Dohmen K, Nakamuta M, Azuma K, Koyanagi T, Yamashita N, Yanagita K, Ichiki Y, Kuniyoshi M, Yamashita N, Morita C, Sugimoto R, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: kuniyoshi m. J Gastroenterol Hepatol. 2022 Feb;37(2):371-377. doi: 10.1111/jgh.15703. Epub 2021 Oct 24. J Gastroenterol Hepatol. 2022. PMID: 34618379
84 results